TY - GEN
T1 - Design of optimally sparse dosing strategies for neural pharmacology
AU - Kumar, Gautam
AU - Ching, Shinung
N1 - Publisher Copyright:
© 2015 American Automatic Control Council.
PY - 2015/7/28
Y1 - 2015/7/28
N2 - Modeling the actions of neuroactive drugs has typically been limited to two classes of mathematical descriptions: the so-called pharmacokinetics model, which describes the diffusion of the drug from the administration site to the effect site, i.e., the brain; and the pharmacodynamics model, which describes the mapping between effect site concentration and behavioral phenotype. Often, a desired behavioral outcome occurs at the end of the admissible concentration range such as unconsciousness induced via a general anesthetic. Here, we develop a dynamical systems-based modeling and design paradigm to optimally construct pharmacologic regimes, i.e., drug selection and dose schedules, to meet phenotypic objectives while minimizing costs and adverse effects. Our framework focuses less on the kinetics of the drug from infusion to effect site, and more on the explicit descriptions of the affinity of the drugs to their respective molecular targets. Through this paradigm, we use methodologies embedded in formal optimal control theory to show how one can, in a principled manner, optimize selection and dosing of synergistic drugs to efficiently achieve a particular phenotype while mitigating paradoxical or undesired states that might otherwise be encountered.
AB - Modeling the actions of neuroactive drugs has typically been limited to two classes of mathematical descriptions: the so-called pharmacokinetics model, which describes the diffusion of the drug from the administration site to the effect site, i.e., the brain; and the pharmacodynamics model, which describes the mapping between effect site concentration and behavioral phenotype. Often, a desired behavioral outcome occurs at the end of the admissible concentration range such as unconsciousness induced via a general anesthetic. Here, we develop a dynamical systems-based modeling and design paradigm to optimally construct pharmacologic regimes, i.e., drug selection and dose schedules, to meet phenotypic objectives while minimizing costs and adverse effects. Our framework focuses less on the kinetics of the drug from infusion to effect site, and more on the explicit descriptions of the affinity of the drugs to their respective molecular targets. Through this paradigm, we use methodologies embedded in formal optimal control theory to show how one can, in a principled manner, optimize selection and dosing of synergistic drugs to efficiently achieve a particular phenotype while mitigating paradoxical or undesired states that might otherwise be encountered.
UR - http://www.scopus.com/inward/record.url?scp=84940912558&partnerID=8YFLogxK
U2 - 10.1109/ACC.2015.7172259
DO - 10.1109/ACC.2015.7172259
M3 - Conference contribution
AN - SCOPUS:84940912558
T3 - Proceedings of the American Control Conference
SP - 5865
EP - 5870
BT - ACC 2015 - 2015 American Control Conference
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 2015 American Control Conference, ACC 2015
Y2 - 1 July 2015 through 3 July 2015
ER -